These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 153953)

  • 41. Depression of lymphocyte transformation and exacerbation of Behcet's syndrome by ingestion of english walnuts.
    Marquardt JL; Snyderman R; Oppenheim JJ
    Cell Immunol; 1973 Nov; 9(2):263-72. PubMed ID: 4584788
    [No Abstract]   [Full Text] [Related]  

  • 42. In vitro parameters of cell-mediated immune reactions in healthy individuals following immune-stimulation attempts with levamisole.
    Thulin H; Thestrup-Pedersen K; Ellegaard J
    Acta Allergol; 1975 Apr; 30(1):9-18. PubMed ID: 125516
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of rheumatoid arthritis with levamisole: long-term results and immune changes.
    Runge LA; Pinals RS; Tomar RH
    Ann Rheum Dis; 1979 Apr; 38(2):122-7. PubMed ID: 375847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Levamisole-mediated restoration of cellular immunity in peripheral blood lymphocytes of patients with immunodeficiency diseases.
    Lieberman R; Hsu M
    Clin Immunol Immunopathol; 1976 Jan; 5(1):142-6. PubMed ID: 1261096
    [No Abstract]   [Full Text] [Related]  

  • 45. Analysis of interleukin-2 activity in patients with Behçet's disease. Ability of T cells to produce and respond to interleukin-2.
    Sakane T; Suzuki N; Ueda Y; Takada S; Murakawa Y; Hoshino T; Niwa Y; Tsunematsu T
    Arthritis Rheum; 1986 Mar; 29(3):371-8. PubMed ID: 3083826
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutrophil-potentiating factors released from stimulated lymphocytes; special reference to the increase in neutrophil-potentiating factors from streptococcus-stimulated lymphocytes of patients with Behçet's disease.
    Niwa Y; Mizushima Y
    Clin Exp Immunol; 1990 Mar; 79(3):353-60. PubMed ID: 2180598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levamisole as an immunopotentiator for T cell deficiency.
    Taki HN; Schwartz SA
    Immunopharmacol Immunotoxicol; 1994 May; 16(2):129-37. PubMed ID: 8077602
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
    Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibitory effect of levamisole and adriamycin on rat mammary cancer induced by 7,12-dimethylbenz(a)anthracene.
    Tominaga T; Kitamura M; Saito T; Itoh I
    Eur J Cancer (1965); 1980 Nov; 16(11):1489-93. PubMed ID: 6785092
    [No Abstract]   [Full Text] [Related]  

  • 50. Lymphoproliferative responses induced by streptococcal antigens in recurrent aphthous stomatitis and Behcet's syndrome.
    Martin DK; Nelms DC; Mackler BF; Peavy DL
    Clin Immunol Immunopathol; 1979 Jun; 13(2):146-55. PubMed ID: 455802
    [No Abstract]   [Full Text] [Related]  

  • 51. Lymphocyte abnormalities in Behçet's syndrome.
    Denman AM; Fialkow PJ; Pelton BK; Salo AC; Appleford DJ; Gilchrist C
    Clin Exp Immunol; 1980 Oct; 42(1):175-85. PubMed ID: 6161726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of levamisole (NSC-177023) on DNA synthesis by lymphocytes from immunosuppressed C57BL mice.
    Woods WA; Filegelman MJ; Chirigos MA
    Cancer Chemother Rep; 1975; 59(3):531-6. PubMed ID: 128409
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A selective loss of T4 cells responding to autologous non-T cells in some patients with Behçet's disease].
    Kotani H; Sakane T; Takada S; Tsunematsu T; Yamana S; Aoi K; Yamamoto M
    Ryumachi; 1983 Feb; 23(1):19-25. PubMed ID: 6223384
    [No Abstract]   [Full Text] [Related]  

  • 54. Levamisole in chronic inflammatory diseases.
    Wilton JM
    J Rheumatol Suppl; 1978; 4():101-13. PubMed ID: 366135
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Levamisole potentiation of antigen specific lymphocyte blastogenic response in Brucella abortus exposed but nonresponsive cattle.
    Kaneene JM; Okino FC; Anderson RK; Muscoplat CC; Johnson DW
    Vet Immunol Immunopathol; 1981 Feb; 2(1):75-85. PubMed ID: 6806973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of levamisole on cell-mediated immune responses in patients with nasopharyngeal carcinoma.
    Goh EH; Chan SH; Simons MJ
    IARC Sci Publ (1971); 1978; (20):503-10. PubMed ID: 730200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Levamisole and skin disease.
    Allen DE; Kaplan B; Pinnell SR
    Int J Dermatol; 1978 May; 17(4):287-300. PubMed ID: 350782
    [No Abstract]   [Full Text] [Related]  

  • 58. Modifying action of levamisole on the course of adjuvant-induced polyarthritis in rats.
    Brajczewska-Fischer W; Szpilman H; Ryzèwska A
    Arch Immunol Ther Exp (Warsz); 1979; 27(1-2):241-6. PubMed ID: 444037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of structural variations in synthetic glycolipids upon mitogenicity for spleen lymphocytes, adjuvancy for humoral immune response and on anti-tumour potential.
    Nigam VN; Bonaventure J; Chopra C; Brailovsky CA
    Br J Cancer; 1982 Nov; 46(5):782-93. PubMed ID: 6756461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human monocyte-lymphocyte interaction and its enhancement by levamisole.
    Kazura JW; Negendank W; Guerry D; Schreiber AD
    Clin Exp Immunol; 1979 Feb; 35(2):258-68. PubMed ID: 312172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.